HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Short Interest Update
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 1,505,393 shares, a growth of 27.3% from the July 14th total of 1,182,654 shares. Based on an average daily volume of 321,258 shares, the short-interest ratio is presently 4.7 days. Approximately 25.6% of the company’s shares are short sold.
A number of hedge funds have recently added to or reduced their stakes in the company. UBS Group AG bought a new stake in HTG Molecular Diagnostics during the first quarter worth approximately $137,000. Two Sigma Securities LLC bought a new stake in HTG Molecular Diagnostics during the first quarter worth approximately $150,000. Granahan Investment Management Inc. MA bought a new stake in HTG Molecular Diagnostics during the first quarter worth approximately $228,000. Renaissance Technologies LLC boosted its stake in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares during the period. Finally, Vanguard Group Inc. boosted its stake in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares during the period. Institutional investors own 28.05% of the company’s stock.
Shares of HTG Molecular Diagnostics (NASDAQ HTGM) opened at 2.22 on Friday. The company’s market cap is $21.69 million. The company’s 50-day moving average is $2.43 and its 200 day moving average is $3.36. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60). The company had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. Equities analysts anticipate that HTG Molecular Diagnostics will post ($2.25) EPS for the current year.
A number of brokerages have recently weighed in on HTGM. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Saturday. HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Canaccord Genuity boosted their price objective on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a “hold” rating in a research note on Wednesday, April 19th. Finally, Rodman & Renshaw boosted their price objective on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.75.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/13/htg-molecular-diagnostics-inc-nasdaqhtgm-short-interest-update.html.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.